Good news for the approximately two million Americans withpsoriatic arthritis (PsA). Those with active disease now have two new treatment options: the U.S. Food and Drug Administration (FDA) in December approved both ixekizumab (Taltz) and tofacitinib (Xeljanz) for thetreatment of PsA.
Continue readingFDA Approves Two New Drugs for Psoriatic Arthritis